| Literature DB >> 33760961 |
Katja Dicke1, Vasileios Dervenis2, Axel Hauschild3, Thomas Dirschka2.
Abstract
Merkel cell carcinoma (MCC) is a rare and aggressive form of skin cancer. Many people suffer early local recurrences and distant metastases. The anti-PDL1 (PDL1: programmed death ligand 1) antibody avelumab has been approved as first-line treatment for advanced MCC in Europe. It is also an alternative treatment for old and multimorbid patients.Entities:
Keywords: Avelumab; Immune checkpoint inhibitors; Multimorbid patient; Programmed cell death-ligand 1 inhibitor; Skin cancer
Year: 2021 PMID： 33760961 DOI： 10.1007/s00105-021-04799-0
Source DB: PubMed Journal: Hautarzt ISSN： 0017-8470 Impact factor: 0.751